An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 28 Sep 2017 Planned End Date changed from 1 Dec 2022 to 1 Sep 2022.
- 28 Sep 2017 Planned primary completion date changed from 1 Dec 2022 to 1 Sep 2022.
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.